AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06312813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: 4% amitriptyline
Study NCT06312813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: 0.1ml propylene glycol
Study NCT05834400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Optimal Lymph FLow (TOLF)
Description: Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.
Study NCT05834400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Monitoring
Description: Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
Study NCT05834400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Monitoring
Description: Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
Study NCT06035120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeriSeal System
Description: The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
Study NCT06425523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Gardening Intervention (HGI)
Description: The Home Gardening Intervention (HGI) provides refugee participants with agricultural inputs and training (field prep., sowing, water management, pest control, weeding, etc.) through a participatory field school approach with a curriculum derived from best practices in agro-ecology. The program includes active monitoring during a 12-month period. The training involves nutrition education on cooking methods and the importance of dietary diversity using garden produce as well as guidance on surplus management and market support. The overall goal of the intervention is to enable climate-resilient farming for improved food security and dietary diversity that is sustainable long-term.
Study NCT06425523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Plus (SH+)
Description: Self-Help Plus (SH+) is a 5-session group intervention developed by the WHO and based on Acceptance and Commitment Therapy, delivered by trained local facilitators. It provides tools to manage stress and adversity through pre-recorded audio lessons and a self-help book. Sessions include individual exercises and group discussions.~SH+ aims to decrease psychological distress. It has shown effectiveness among refugees in Uganda and elsewhere.
Study NCT06425523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: The Enhanced Usual Care (EUC) control condition involves a single 15-minute psychoeducation session providing information on managing overthinking and utilizing available mental health services in the settlement. These services include psychosocial support from community health workers and clinical mental health services (counseling and medications) provided weekly at local primary care centers by a visiting team.
Study NCT06425523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EUC)
Description: The Enhanced Usual Care (EUC) control condition involves a single 15-minute psychoeducation session providing information on managing overthinking and utilizing available mental health services in the settlement. These services include psychosocial support from community health workers and clinical mental health services (counseling and medications) provided weekly at local primary care centers by a visiting team.
Study NCT06574126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: Dara-VRD followed by apheresis and cilta-cel infusion
Description: In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
Study NCT06574126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion
Description: In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
Study NCT05735184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration
Study NCT06067425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442501
Description: Solution for injection; Subcutaneous injection
Study NCT05938270 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saruparib (AZD5305)
Description: Saruparib (AZD5305) given orally once daily
Study NCT05938270 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Darolutamide
Description: Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
Study NCT05938270 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Treatment
Description: No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
Study NCT05350774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: IV normal saline 250ml for 5 days
Study NCT05350774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin
Description: IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
Study NCT04704648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical
Description: The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency.
Study NCT05244239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given IV
Study NCT05244239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo RT
Study NCT06137118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: Investigational Product administered via intravenous infusion.
Study NCT05443165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effectiveness of the online decision support system developed for symptom self-management
Description: The online decision support system will appear with mild, moderate, or high severity according to symptom severity. If the patient's symptom is of mild category severity, a green area will appear on the screen and patients will see information on self-management strategies in this area. If patient's symptom is of moderate category severity, a yellow area will appear on the screen and patients will see information on self-management strategies and symptom monitoring at home in this area. In moderate symptom severity, when a yellow area occurs, patients should be asked, Is your fever above 38℃? according to their needs. Information about the treatment steps to be followed will be given. If the patient's symptom is in a severe category, a red area will appear on the screen and the patients will be warned to apply to the healthcare institution within this area.
Study NCT05443165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom self-management with an education booklet
Description: Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS.
Study NCT05683041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalobarrier
Description: Hyalobarrier is a viscous, transparent gel and is used as a preventive measure for post-operative adhesions in the abdominal and uterine cavity.
Study NCT05735184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Administration
Study NCT05735184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous or Intravenous Administration
Study NCT05924165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5mg Oxycodone, Q6 PRN
Description: Oxycodone is an opioid that is used to relieve moderate to severe pain.
Study NCT05924165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg Ketorolac, Q6 PRN
Description: Ketorolac is an NSAID used to relieve moderately severe pain.
Study NCT06120283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Planned doses administered orally.
Study NCT06120283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Standard dose administered via intramuscular injection.
Study NCT06120283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Standard dose administered orally as a tablet.
Study NCT06502717 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study NCT06205420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable composite resin restoration
Description: The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and highly filled flowable composite will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel.
Study NCT06205420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable giomer restoration
Description: The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel.
Study NCT02438202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thymatron IV device (Somatics)
Description: Patients will be treated with a modified routine ECT/maintenance ECT series.
Study NCT05861986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risdiplam
Description: Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
Study NCT05544136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FMISO PET/CT scan
Description: 18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start
Study NCT05544136 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy
Description: * 18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes).~* 18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes.
Study NCT05544136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
Study NCT06300307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-01
Description: Solution for infusion
Study NCT05735184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Intravenous Administration
Study NCT05735184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous Administration
Study NCT06300307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion
Study NCT06503146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FAPI-74
Description: Participants will receive a single intravenous (IV) dose of \[18F\]FAPI-74 prior to PET/CT imaging.
Study NCT06503146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FDG
Description: 18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.
Study NCT06303193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pacritinib
Description: Pacritinib will be administered orally on a continuous basis for 28 day cycles without a rest period between cycles. Dose assigned by dose level/phase.
Study NCT06179160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB161734
Description: INCB161734 will be administered at protocol defined dose.
Study NCT06597591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR headset
Description: 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
Study NCT06597591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet
Description: 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a tablet. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
Study NCT06223633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PK Papyrus Covered Coronary Stent System
Description: PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
Study NCT06694155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate Crossover
Description: This crossover intervention includes 1 week of whey protein isolate supplementation and 1 week of placebo supplementation.
Study NCT06694155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 week of Non-whey protein Placebo supplement
Study NCT05931406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: A normal working day from of 12h
Study NCT05931406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-and-stand desk
Description: a working day during which the participants have to get up at least 5 min/hour
Study NCT05931406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycloergometer
Description: a working day during which they can use a cycloergometer installed under the desk
Study NCT06696508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insitu Spatulation with Pre-Dismembering Ureteropelvic Angle Suturing during laparoscopic pyeloplasty
Description: After proper dissection of the PUJ, the anterior wall of the renal pelvis was incised.~The incision continued downwards and laterally towards the PUJ and the lateral aspect of the ureter.~In cases where crossing vessels were present, the pelvis with the PUJ and the uppermost part of the ureter were properly dissected from these vessels. This gave a wide room for pulling the pelvis upwards and gentle retraction of the crossing vessels allowing incision of the anterior wall of the pelvis and starting the spatulation of the PUJ. Spatulation could then continue to the upper ureter behind the properly dissected and retracted vessels.~After complete spatulation and before dismembering the PUJ, we made benefit of splinting the ureter in place; a Maryland grasper opened the lumen of the ureter and the first stitch was precisely placed from outside inwards at the proper angle of the ureteric spatulation using 5/0 Vicryl sutures.~The posterior wall of the PUJ and the pelvis was then dismembered
Study NCT06696508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Laparoscopic Dismembered Pyeloplasty
Description: the PUJ was dismembered after proper dissection, the lateral aspect of the ureter was spatulated and the first stich was also placed in the spatulation angle from outside inwards. All these steps were done after the discontinuation of the ureter and the pelvis, losing the benefit of ureteric splinting and orientation
Study NCT06699511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise
Study NCT06699082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KinesioTaping and Keltonborn Mobilization
Description: Experimental group was treated with kinesiotape and kaltenborn mobilization while the non experimental group was treated with conventional therapy along with kaltenborn mobilization.
Study NCT06699082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KinesioTaping and Keltonborn Mobilization
Description: Experimental group was treated with kinesiotape and kaltenborn mobilization while the non experimental group was treated with conventional therapy along with kaltenborn mobilization.
Study NCT06698419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RADA16 gel application into mastoid cavity
Description: A single application of RADA16 gel will be applied along the surface of the mastoid cavity intraoperatively prior to insertion of gelatin sponge packing. Application will involve a thin layer of gel just enough to cover the entire surface of the cavity.